Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Interventional, Open-Label, Single-Arm Trial of Oral Ibezapolstat (ACX-362E) for Treatment and Reduction of Recurrent Clostridioides Difficile Infection in Patients With Multiple Recurrent Infections (IBZ-PATHFINDER)

NCT07513285 is registered in ClinicalTrials.gov with Acurx Pharmaceuticals Inc. as lead sponsor.

NCT NCT07513285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07513285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Interventional, Open-Label, Single-Arm Trial of Oral Ibezapolstat (ACX-362E) for Treatment and Reduction of Recurrent Clostridioides Difficile Infection in Patients With Multiple Recurrent Infections (IBZ-PATHFINDER)
Lead sponsor
Acurx Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 6, 2026
Completion date
November 24, 2027
Enrollment
20 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile infection recurrence